Where do these injections fit in my OA plan

“Should I consider newer injections like exosomes or an ultrasound‑guided hip injection, and how do they compare with options a GP might already mention for osteoarthritis?”

In practical terms, injections usually sit in the middle of the osteoarthritis (OA) plan: after core measures such as exercise/physiotherapy, weight management, simple supports and oral pain relief have been tried, and before (or alongside) discussions about joint replacement when symptoms remain limiting. Intra‑articular injections are generally positioned as less invasive than surgery and may offer local pain relief, but evidence quality varies by product and joint. [1]

Injections aim to reduce pain and improve day‑to‑day function; none is proven to “cure” OA or reliably regrow cartilage.

A useful way to sort the options—based on today’s evidence and regulation—is:

• Commonly used for hip OA symptom control (with mixed trial evidence): intra‑articular corticosteroid injections are widely used in practice, but a 2025 systematic review/meta-analysis of RCTs found no statistically significant WOMAC or VAS differences versus placebo or hyaluronic acid at assessed time points, suggesting average benefit may be modest/uncertain when tested rigorously. [2]
• More mature randomised evidence in knee OA: PRP has multiple randomised trials and a 2025 meta‑analysis (18 RCTs; n=1995) reporting clinically meaningful improvements versus placebo up to 12 months, with outcomes influenced by platelet concentration. [3] A separate platelet-dose systematic review also reported better outcomes in higher-dose PRP arms than lower-dose arms. [4]
• Single‑injection option with a growing (mainly observational) knee OA evidence base: polyacrylamide hydrogel (PAAG; Arthrosamid®) has prospective open‑label evidence including a 5‑year extension study after a single 6 mL injection, but without a control group. [5] A separate 24‑month cohort reported improvements in PROMs alongside subsequent knee replacements and recorded complications in a substantial proportion of treated knees. [6]
• Early experimental stage in knee OA: mesenchymal stem cell (MSC)‑derived exosomes/extracellular vesicles have supportive preclinical evidence from rat models, including a 2025 systematic review/meta-analysis of 28 studies reporting improved histological cartilage scores and shifts in inflammatory/anabolic markers. [7]

The sections that follow focus on two threads: (1) what the knee OA evidence shows for exosomes compared with better‑studied options such as PRP and PAAG, and (2) what changes—technically and practically—when injections are done into the hip (where evidence quality and product choices differ from the knee and many biologic options are still described as investigational in reviews). [1]

Exosome injections for knee OA why they are still experimental

Exosomes (often described in research papers as “extracellular vesicles”) are tiny membrane-bound packages released by cells, including mesenchymal stromal/stem cells (MSCs). They carry signalling molecules (such as proteins and genetic material) that may alter how tissues behave.

The strongest “why this might work” evidence currently comes from animal models, not people. A 2025 systematic review and meta-analysis of 28 rat studies reported that MSC-derived exosomes tended to make OA cartilage look healthier under the microscope and shifted lab readouts towards repair rather than inflammation, including higher anabolic markers and lower inflammatory mediators. [7]

What that does—and does not—mean is important: these are promising biological signals in rats, and they do not by themselves prove meaningful symptom improvement in humans.

Taken together, the evidence base currently supports one cautious conclusion: exosome injections remain experimental for knee osteoarthritis, because the best-published evidence to date is predominantly preclinical rather than large, placebo-controlled human trials showing clear clinical benefit. [7]

Comparing exosomes with PRP and Arthrosamid for the knee

The headline comparison in 2024–2025 is less about which injection sounds newest, and more about which one has the strongest track record for improving knee OA symptoms in humans. Set side by side, PRP has the most randomised trial evidence (including placebo-controlled meta-analyses), polyacrylamide hydrogel (PAAG; Arthrosamid®) has a growing but largely observational evidence base with a single‑injection profile, and exosomes remain earlier-stage with evidence syntheses still dominated by animal studies. [3,5,7]

Which has the strongest human evidence that it helps symptoms?

For PRP, the best summary comes from a 2025 meta-analysis of 18 randomised trials (n=1995) versus placebo, reporting statistically and clinically meaningful improvements in pain (VAS) and function (WOMAC) through 12 months in several time windows. [3]

A separate 2024 dose-focused systematic review suggests outcomes may be influenced by platelet dose, with treatment arms reporting statistically “positive” results having higher mean platelet dose than non-positive arms. [4]

By contrast, exosomes currently have far less human comparative evidence in knee OA in the peer-reviewed literature, with the most comprehensive synthesis evidence still drawn from preclinical (rat) disease models. [7]

For PAAG (Arthrosamid), the published clinical story is different again: evidence is accumulating, but it is mostly open-label and cohort data rather than placebo-controlled randomised trials. A 5‑year extension study after a single 6 mL injection reported sustained improvements in WOMAC domains and patient global assessment, but without a control group and with attrition over time. [5] A separate 24‑month cohort reported symptomatic improvement overall while also recording subsequent knee replacements and complications in treated knees. [6]

How do PRP and PAAG compare with ‘standard’ steroid injections?

A systematic review of randomised trials published across 2019–2024 found both PRP and corticosteroid injections generally improved pain and function, with PRP often appearing more durable over follow-up, while highlighting that PRP preparation and protocols vary across studies. [8]

Treatment profile and expectations (what the injection is trying to do)

PRP is typically framed as a biologically active, patient-derived injection where outcomes may depend on how it is prepared (including platelet dose). [4] PAAG studies commonly evaluate a single 6 mL injection approach with follow-up in prospective open-label and cohort designs. [5,6] Exosomes are best viewed, on today’s published evidence base, as investigational and still largely supported by animal-model data. [7]

Ultrasound‑guided hip injections what actually happens

In many services, a hip injection enters the picture when hip osteoarthritis pain has become hard to settle with exercise-based rehabilitation, simple painkillers and activity modification—especially during a clearly painful flare. Narrative reviews describe intra‑articular injections as a way to deliver local therapy that may reduce pain with fewer systemic adverse effects than oral medications, while also being less invasive than surgery—though evidence quality varies by product and many biologic options remain investigational in hip OA. [1]

In terms of what is injected, glucocorticoid (corticosteroid) injections are commonly discussed in hip OA care pathways, but when rigorously pooled in RCT meta-analysis, average benefits versus placebo or hyaluronic acid may be modest or uncertain at assessed time points. [2]

A typical appointment is an outpatient injection rather than an operation, and some services use imaging guidance (for example ultrasound or fluoroscopy) to help place the needle accurately into the joint.

Hip injections are often used to create a window for walking, sleep and physiotherapy to become more manageable, not as a stand-alone cure for osteoarthritis. [1]

How hip injections differ from knee injections

A common question is: “My knee injection was done quickly in clinic – why is my hip injection talked about differently?” The short answer is that the two joints behave differently as injection targets, and the evidence base for what to inject (and what to expect) is not identical between hip and knee.

Access and accuracy: why guidance is often discussed more in the hip

The hip is a deeper joint than the knee, so services more commonly discuss imaging guidance for hip injections (for example ultrasound or fluoroscopy) to help with needle placement.

What is usually injected, and how strong is the evidence?

In the hip OA literature, corticosteroid injections remain a commonly discussed option, but a 2025 systematic review/meta-analysis reported no statistically significant WOMAC or VAS improvements versus placebo or hyaluronic acid at the assessed time points—pointing to modest or uncertain average benefit when tested rigorously. [2]

By comparison, the knee has a larger placebo-controlled randomised evidence base for some injectables. For example, PRP has a 2025 meta-analysis of 18 RCTs (n=1995) versus placebo reporting clinically meaningful pain and function improvements through 12 months. [3]

In contemporary reviews of hip OA injection therapies, several biologic options (including PRP and MSC-based products) are still described as investigational due to limitations in evidence quality and consistency. [1]

Deciding on injections and planning next steps

Decision-making usually comes down to a handful of practical questions, anchored in what has (and has not) been shown in published studies up to 2024–2025.

• Are exosome injections ready for routine knee OA care? The most comprehensive synthesis evidence available in 2025 is still predominantly preclinical: a systematic review/meta-analysis of 28 rat studies reported improved histological cartilage findings and favourable shifts in inflammatory/anabolic markers. [7] On that basis, exosomes are best treated as experimental/investigational for knee OA until larger, placebo-controlled human trials show consistent clinical benefit.
• How do PRP and PAAG (Arthrosamid) fit in? PRP has multiple RCTs and a 2025 meta-analysis (n≈1,995) reporting clinically meaningful symptom improvement versus placebo up to 12 months, with outcomes influenced by platelet concentration; a 2024 systematic review also supports a platelet-dose relationship. [3,4] PAAG has growing observational data, including a 5‑year open-label extension study and a separate 24‑month cohort reporting symptom improvements alongside real‑world events such as subsequent knee replacement and recorded complications. [5,6]
• What tends to be realistic from a hip injection? Reviews describe hip intra-articular injections as less invasive than surgery and potentially useful for local pain relief, but they also emphasise variable evidence quality and that many biologic hip injections remain investigational. [1] When corticosteroid injections are pooled in RCT meta-analysis, average benefits versus placebo or hyaluronic acid may be modest/uncertain at assessed time points. [2]

A simple knee OA “next steps” framework used in clinic is:

• Build from conservative care, then match injection choice to goals (short-term flare control vs longer symptom window), OA stage, and medical history.
• Treat exosomes as a research-stage option given the current predominance of animal-model evidence. [7]

Safety and due-diligence prompts that apply to any joint injection (knee or hip) include: who is performing the injection and how often; exactly what product is being injected and whether it is licensed for that use; what human evidence exists in the same joint; and what the plan is if there is no benefit at 6–12 weeks.

No injection can guarantee avoiding joint replacement: response varies, with some people reporting substantial relief, others modest change, and some no improvement at all.

1. [1] The Current Status and Future Prospects of Intra-articular Injection Therapy for Hip Osteoarthritis: A Review. (2025). https://doi.org/10.1007/s11916-025-01378-z https://doi.org/10.1007/s11916-025-01378-z
2. [2] Mesenchymal stem cell-derived exosomes for the treatment of knee osteoarthritis: a systematic review and meta-analysis based on rat model. (2025). https://doi.org/10.3389/fphar.2025.1588841 https://doi.org/10.3389/fphar.2025.1588841